GSK plc (LON:GSK) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of GSK plc (LON:GSK - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seven brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is GBX 1,805.83 ($23.97).

Separately, JPMorgan Chase & Co. reaffirmed an "underweight" rating on shares of GSK in a research report on Friday, March 28th.

Insider Transactions at GSK

In related news, insider Wendy Becker acquired 536 shares of the business's stock in a transaction on Thursday, March 20th. The stock was purchased at an average cost of GBX 1,515 ($20.11) per share, for a total transaction of £8,120.40 ($10,776.91). Also, insider Emma Walmsley sold 38,459 shares of the company's stock in a transaction that occurred on Monday, February 17th. The shares were sold at an average price of GBX 1,418 ($18.82), for a total value of £545,348.62 ($723,753.97). 1.61% of the stock is currently owned by corporate insiders.

GSK Stock Up 0.6 %

Shares of GSK stock opened at GBX 1,370 ($18.18) on Thursday. The firm has a market cap of £55.59 billion, a PE ratio of 22.13, a P/E/G ratio of 1.24 and a beta of 0.31. The business's 50 day simple moving average is GBX 1,433.84 and its 200 day simple moving average is GBX 1,402.33. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. GSK has a 52-week low of GBX 1,242.50 ($16.49) and a 52-week high of GBX 1,823.50 ($24.20).

GSK (LON:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported GBX 23.20 ($0.31) EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. On average, analysts predict that GSK will post 175.980975 earnings per share for the current fiscal year.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.